What happened
Opentrons a New York-based laboratory robotics and automation company has raised $40 million in Series E financing led by healthcare investment firm Avego The funding will support the expansion of Opentrons' robotics artificial intelligence software and laboratory data infrastructure as the company seeks to accelerate the adoption of autonomous scientific experimentation Opentrons plans to invest in AI-driven experimental execution expand the capabilities of its laboratory automation systems and enter additional markets and geographic regions
Opentrons has raised $40 million in Series E financing led by Avego The funding will support the expansion of Opentrons' robotics artificial intelligence software and laboratory data infrastructure Opentrons plans to invest in AI-driven experimental execution expand the capabilities of its laboratory automation systems and enter additional markets and geographic regions The company has deployed more than 11,000 robots across laboratories in over 80 countries including installations at 90% of the world's 20 largest pharmaceutical companies Its customer base also includes every top-20 U.S. research university and 14 of the 15 largest global biopharmaceutical companies
Why it matters
The funding will enable Opentrons to scale its laboratory automation platform as research organizations seek to connect AI-based scientific discovery with automated physical experimentation This has the potential to accelerate the adoption of autonomous scientific experimentation and improve the efficiency of laboratory workflows Opentrons' technology is designed to support a continuous feedback process in which experimental results inform subsequent research decisions The company's open technology architecture is intended to allow laboratories to incorporate its systems into existing research environments rather than relying exclusively on proprietary automation ecosystems
The funding will enable Opentrons to scale its laboratory automation platform as research organizations seek to connect AI-based scientific discovery with automated physical experimentation This has the potential to accelerate the adoption of autonomous scientific experimentation and improve the efficiency of laboratory workflows Opentrons' technology is designed to support a continuous feedback process in which experimental results inform subsequent research decisions The company's open technology architecture is intended to allow laboratories to incorporate its systems into existing research environments rather than relying exclusively on proprietary automation ecosystems Opentrons' investors include Avego BroadOak Capital Partners SoftBank Khosla Ventures Sands Capital Lerer Hippeau and Y Combinator
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
crm_get_transaction(id='4092').A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
What to watch next
The impact of Opentrons' AI-driven laboratory automation on the scientific community and the potential for increased efficiency and accuracy in laboratory workflows
The impact of Opentrons' AI-driven laboratory automation on the scientific community The potential for increased efficiency and accuracy in laboratory workflows The role of AI in accelerating the adoption of autonomous scientific experimentation The expansion of Opentrons' robotics artificial intelligence software and laboratory data infrastructure The company's plans to enter additional markets and geographic regions